ADXS — Advaxis Share Price
Last Trade - 00:00- $57.15m
- $9.04m
- $2.99m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Oct | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 3.99 | 12.03 | 6.06 | 20.88 | 0.25 | 2.99 | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Advaxis, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of Listeria monocytogenes (Lm)-based antigen delivery products. The Company is using its Lm platform directed against tumor-specific targets to engage the patient's immune system to destroy tumor cells. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. Its Lm platform technology has clinical activity in several programs. These Lm strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment (TME) to enable the T-cells to eliminate tumors.
Directors
- David Sidransky NEC (60)
- Kenneth Berlin PRE (56)
- James Patton NVC (63)
- Andres Gutierrez (61)
- Igor Gitelman CAO (45)
- Roni Appel IND (54)
- Richard Berman (78)
- Samir Khleif (57)
- Last Annual
- October 31st, 2020
- Last Interim
- April 30th, 2021
- Incorporated
- February 28th, 2002
- Public Since
- July 28th, 2005
- No. of Employees
- 18
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 145,638,459
- Address
- 9 DEER PARK DRIVE, SUITE K-1, MONMOUTH JUNCTION, 08852
- Web
- https://www.advaxis.com/
- Phone
- +1 7325451590
- Contact
- Tim McCarthy
- Auditors
- Marcum LLP
Latest News for ADXS
Upcoming events for ADXS
Q3 2021 Advaxis Inc Earnings Release
Similar to ADXS
ABEONA THERAPEUTICS ORD
NASDAQ Capital Market
ACASTI PHARMA CL A ORD
NASDAQ Capital Market
ACHIEVE LIFE SCIENCES ORD
NASDAQ Capital Market
ACURX PHARMACEUTICALS ORD
NASDAQ Capital Market
ADDEX THERAPEUTICS ADR
NASDAQ Capital Market
FAQ
As of Today at 19:59 UTC, shares in Advaxis are trading at $0.39. This share price information is delayed by 15 minutes.
Shares in Advaxis last closed at $0.39 and the price had moved by -23.51% over the past 365 days. In terms of relative price strength the Advaxis share price has underperformed the S&P500 Index by -41.97% over the past year.
The overall consensus recommendation for Advaxis is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Advaxis does not currently pay a dividend.
Advaxis does not currently pay a dividend.
Advaxis does not currently pay a dividend.
To buy shares in Advaxis you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.39, shares in Advaxis had a market capitalisation of $57.15m.
Here are the trading details for Advaxis:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ADXS
Based on an overall assessment of its quality, value and momentum Advaxis is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Advaxis is $2.25. That is 473.39% above the last closing price of $0.39.
Analysts covering Advaxis currently have a consensus Earnings Per Share (EPS) forecast of -$0.17 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Advaxis. Over the past six months, its share price has underperformed the S&P500 Index by -71.41%.
As of the last closing price of $0.39, shares in Advaxis were trading -29.49% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for Advaxis.
Advaxis' management team is headed by:
- David Sidransky - NEC
- Kenneth Berlin - PRE
- James Patton - NVC
- Andres Gutierrez -
- Igor Gitelman - CAO
- Roni Appel - IND
- Richard Berman -
- Samir Khleif -
We do not have data on Advaxis' shareholders